MedtechLedger currently links 310 FDA records to the applicant name Medtronic, Inc.. The collection includes 11 510(k) clearances. It includes 11 original PMA approvals. 70 entries are PMA supplements. 218 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Mar 14, 1988 to Nov 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NVZ appears in 40 of the 310 linked filings. The collection spans 28 FDA product codes and 29 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P960009, with 40 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 31 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 7000 Central Ave., NE, Minneapolis, MN, 55432. Recorded on P960009/S545, decision dated Nov 8, 2026.
FDA approved a supplement to PMA P960009, not a new whole-system approval. The record ties S545 to the Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (B32000), and the stated change is limited to a size change for the lead insertion tool.
The decision text also names a change in tip width dimension verification testing, but it does not supply the original measurement, the revised measurement, or any clinical rationale. The supplement type is listed as Real-Time Process, with a Process Change - Manufacturer/Sterilizer/Packager/Supplier reason.
FDA approval-order wording
approval for dimensions size change for lead insertion tool and modification to tip width dimension verification testing.
FDA lists this action as a 30-Day Notice supplement to PMA P130021/S188 for Medtronic’s Evolut FX delivery catheter system within the Evolut FX transcatheter aortic valve system. The database record frames it as a process change, not a new PMA and not a new approval of the whole system.
The only changed item described in the supplied text is “the introduction of an automated vision system for the detection of flash.” The record does not say what “flash” refers to, where the vision system is used in the manufacturing chain, or whether any device design, indication, or clinical evidence changed.
FDA approval-order wording
the introduction of an automated vision system for the detection of flash
FDA lists this as supplement P860004/S465 to the SynchroMed Infusion System, Ascenda Intrathecal Catheters PMA. The decision is a 30-Day Notice for a process change, so the record describes manufacturing changes tied to the existing approved system rather than a new approval of the whole device.
The specific changes are a new surface mount technology production line, a revised SMT process sequence with automated optical inspection after each SMT assembly stage, and added solder paste inspection plus a qualified de-paneling machine for PCBA production. The source does not provide clinical data, a new indication, or device performance results; it only states the manufacturing scope of the notice.
FDA approval-order wording
approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production
The FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-30 for P960009/S548, a supplement to Medtronic, Inc.'s Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense. The device category is an implanted electrical stimulator for parkinsonian tremor, classified under product code MHY in the Neurology specialty. The supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier.
The recorded scope covers three manufacturing changes: adding a new surface mount technology production line, revising the SMT process sequence so automated optical inspection follows each SMT assembly stage, and adding an equivalent solder paste inspection system plus a qualified de-paneling machine for PCBA production. This action concerns production process and equipment only; it is not an approval of the whole system, and no clinical, efficacy or labeling conclusions follow from the record. The source lists no documents, so inspection criteria, validation data and line qualification details remain unknown.
FDA approval-order wording
approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production
The FDA record lists this 30-Day Notice under P860004/S464 as a process change for a manufacturer, sterilizer, packager or supplier, tied to the SynchroMed Infusion System and Ascenda Intrathecal Catheters. The decision is OK30. The statement covers six revisions, including enhanced operator verification of the FactoryWorks processing step and recorded battery pre-weight, added pre-weight and post-weight out-of-control action plans, and software and HMI updates that automatically reject batteries above the established final-fill reasonable limit.
The statement also covers white work-in-progress trays for electrolyte-filled batteries, an isopropyl alcohol wipe for residual electrolyte, and removal of Ball Press and Button Press certification prerequisites from the ram-change procedure. The identifier links the supplement to the original PMA; the notice itself does not approve the whole system. The record does not provide supporting data, safety or effectiveness findings beyond these described changes.
Whether the removed prerequisites were matched by other process controls is not evident from the statement alone; that specific information is absent.
FDA approval-order wording
1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
Oct 29, 2026 · 30-Day Notice
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
RECALL COVERAGE
Recalls linked to this firm
MedtechLedger links 14 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 14 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.
Z-2810-2026 · FDA links K260195 · Recalling firm: MEDTRONIC PERFUSION SYSTEMS
Z-2811-2026 · FDA links K260195 · Recalling firm: MEDTRONIC PERFUSION SYSTEMS
Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.